nach oben

Current HIV/AIDS Reports

Erschienen in:

01.12.2011 | Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Substance Use: Impact on Adherence and HIV Medical Treatment

verfasst von: Adam Gonzalez, Jennifer Barinas, Conall O’Cleirigh

Erschienen in: Current HIV/AIDS Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Substance use is highly prevalent among people living with HIV/AIDS, is often comorbid with other mental health problems, related to poor HIV medical outcomes, and, is associated with poor medication and treatment adherence. The current review reports on the recent state of the literature in terms of substance use and its relation to HIV medication and treatment adherence, and offers recommendations for advancing treatment and secondary HIV prevention efforts. Identifying substance users within HIV primary care and developing, evaluating, and refining integrative substance use-mental health-adherence interventions may be clinically important targets for effective disease management and may contribute to secondary HIV prevention efforts.

Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200.PubMedCrossRef

Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9.PubMedCrossRef

Parruti G, Manzoli L, Marani Toro P, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS. 2006;20:48–56.PubMedCrossRef

Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–9.PubMedCrossRef

Low-Beer S, Yip B, O’Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–1.PubMedCrossRef

Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed

•• HIV Prevention Trials Network (HPTN-052). Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052). Press Release May 12 2011. http://www.hptn.org/index.htm. This is the first randomized clinical trial to demonstrate that treating an HIV-infected person early with ART, compared to delayed initiation, can reduce the risk of sexual transmission for partners without HIV.

Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.PubMedCrossRef

McGowan CC, Weinstein DD, Samenow CP, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE. 2011;6:e18462.PubMedCrossRef

10.

Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS. 2004;18:S43–8.PubMedCrossRef

11.

Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis. 2007;45:S313–7.PubMedCrossRef

12.

Skeer MR, Mimiaga MJ, Mayer KH, et al. Patterns of substance use among a large urban cohort of HIV-infected men who have sex with men in primary care [published online ahead of print January 15 2011]. AIDS Behav. 2011. http://www.springerlink.com.ezp-prod1.hul.harvard.edu/content/u6548k73233k8587/fulltext.pdf

13.

Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70:505–11.PubMedCrossRef

14.

Amsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.

15.

King WD, Larkins S, Hucks-Ortiz C, et al. Factors associated with HIV viral load in a respondent driven sample in Los Angeles. AIDS Behav. 2009;13:145–53.PubMedCrossRef

16.

Lucas GM, Cheever LW, Chaison RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–9.PubMedCrossRef

17.

•• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–93. A review of the literature that indicates among persons with HIV/AIDS, alcohol use disorders are related to decreased ART adherence and to poorer HIV treatment outcomes.PubMedCrossRef

18.

Friedman MS, Marshal MP, Stall R, et al. Associations between substance use, sexual risk taking and HIV treatment adherence among homeless people living with HIV. AIDS Care. 2009;21:692–700.PubMedCrossRef

19.

•• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52:180–202. This is a meta-analysis of 40 studies indicating that alcohol users with HIV/AIDS are only 47%–60% as likely to be adherent to ART than non-users.PubMedCrossRef

20.

Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103:1242–57.PubMedCrossRef

21.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington DC; 2000.

22.

Gruber VA, Sorensen JL, Haug NA. Psychosocial predictors of adherence to highly active antiretroviral therapy practical implications. J HIV AIDS Soc Serv. 2007;6:23–37.CrossRef

23.

•• Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009;21:953–66. This is a review of 88 studies examining facilitators and barriers related to ART adherence, which highlights substance abuse as a significant barrier to adherence.PubMedCrossRef

24.

Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731–47.PubMedCrossRef

25.

Heffelfinger JD, Voetsch AC, Nakamura GV, et al. Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia. PLoS ONE. 2009;4:e5002.PubMedCrossRef

26.

Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9:S8–S15.PubMed

27.

Conover CJ, Weaver M, Ang A, et al. Costs of care for people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders. AIDS Care. 2009;21:1547–59.PubMedCrossRef

28.

•• Mellins CA, Havens JF, McDonnell C, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009;21:168–77. Data from 1138 adults with HIV/AIDS and comorbid mental and substance abuse disorders indicated that ART nonadherence was related to current alcohol and drug abuse, increased psychological distress, less attendance at medical appointments, nonadherence to psychiatric medication, and lower self-reported spirituality. PubMedCrossRef

29.

Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21:655–63.PubMedCrossRef

30.

When to start consortium et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-indected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–63.CrossRef

31.

Giordano TP, Gifford AL, White Jr AC, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44:1493–9.PubMedCrossRef

32.

Metsch LR, Bell C, Pereyra M, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;99:1045–9.PubMedCrossRef

33.

Josephs JS, Fleishman JA, Korthuis PT, et al. Emergency department utilization among HIV-infected patients in a multisite multistate study. HIV Med. 2010;11:74–84.PubMedCrossRef

34.

Meade CS, Hansen NB, Kochman A, Sikkema KJ. Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse. AIDS Patient Care STDS. 2009;23:259–66.PubMedCrossRef

35.

Ulett KB, Willig JH, Routman JS, et al. The therapeutic implications of timely linkage and early retention in HIV Care. AIDS Patient Care STDS. 2009;23:41–9.PubMedCrossRef

36.

Hessol NA, Weber KM, Holman S, et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health. 2009;18:1627–37.CrossRef

37.

Sohler NL, Coleman SM, Cabral H, et al. Does self-report data on HIV primary care utilization agree with medical record data for socially marginalized populations in the United States? AIDS Patient Care STDS. 2009;23:837–43.PubMedCrossRef

38.

Michel L, Carrieri MP, Fugon L, et al. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANS-EN12-VESPA Study): relevance for clinical management and intervention. AIDS Care. 2010;22:1136–45.PubMedCrossRef

39.

Baum MK, Rafie C, Lai S, et al. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26:511–8.PubMedCrossRef

40.

Iralu J, Duran B, Pearson CR, et al. Risk factors for HIV disease progression in a rural southwest American Indian population. Public Health Rep. 2010;125:43–50.PubMed

41.

Shuper PA, Neuman M, Kanteres F, et al. Causal considerations on alcohol and HIV/AIDS—a systematic review. Alcohol Alcohol. 2010;45:159–66.PubMed

42.

Neblett RC, Hutton HE, Lau B, et al. Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health. 2011;20:279–86.CrossRef

43.

Cheng DM, Libman H, Bridden C, et al. Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol. 2009;43:65–71.PubMedCrossRef

44.

Farley J, Miller E, Zamani A, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care. 2010;9:218–26.CrossRef

45.

• Miguez-Burbano MJ, Lewis JE, Fishman J, et al. The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol. 2009;44:366–71. This study showed that among people with HIV/AIDS, consuming liquor only (compared to beer or wine only) is related to poor CD4 T-cell production and poor viral suppression.CrossRef

46.

Conen A, Fehr J, Glass TR, et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV cohort study. Antivir Ther. 2009;14:349–57.PubMed

47.

Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2010;54:197–203.PubMed

48.

Outlaw A, Naar-King S, Green-Jones M, et al. Predictors of optimal HIV appointment adherence in minority youth: a prospective study. J Pediatr Psychol. 2010;35:1011–5.PubMedCrossRef

49.

Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18:1007–15.PubMedCrossRef

50.

Bhat VG, Ramburuth M, Singh M, et al. Factors associated with poor adherence to anti-retroviral therapy in patients attending a rural health centre in South Africa. Eur J Clin Microbiol Infect Dis. 2010;29:947–53.PubMedCrossRef

51.

Do NT, Phiri K, Bussmann H, et al. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res Hum Retroviruses. 2010;26:685–91.PubMedCrossRef

52.

Fitzgerald M, Collumbien M, Hosegood V. “No one can ask me ‘Why do you take that stuff?’”: men’s experiences of antiretroviral treatment in South Africa. AIDS Care. 2010;22:355–60.PubMedCrossRef

53.

Jaquet A, Ekouevi DK, Bashi J, et al. Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction. 2010;105:1416–21.PubMedCrossRef

54.

Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009;64:599–606.PubMedCrossRef

55.

Silva MCF, Ximenes RAA, Filho DBM, et al. Risk-factors for non-adherence to antiretroviral therapy. Rev Inst Med Trop S Paulo. 2009;51:135–9.PubMedCrossRef

56.

Kalichman SC, Amaral CM, White D, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDS. 2009;23:449–54.PubMedCrossRef

57.

Strauss SM, Tiburcio NJ, Munoz-Plaza C, et al. HIV care providers’ implementation of routine alcohol reduction support for their patients. AIDS Patient Care STDS. 2009;23:211–8.PubMedCrossRef

58.

Velasquez MM, von Sternberg K, Johnson DH. Reducing sexual risk behaviors and alcohol use among HIV-positive men who have sex with men: a randomized clinical trial. J Consult Clin Psychol. 2009;77:657–67.PubMedCrossRef

59.

Papas RK, Sidle JE, Martino S, et al. Systematic cultural adaptation of cognitive-behavioral therapy to reduce alcohol use among HIV infected outpatients in Western Kenya. AIDS Behav. 2010;14:669–78.PubMedCrossRef

60.

Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:443–50.PubMedCrossRef

61.

Longmire-Avital B, Golub SA, Parsons JT. Self-reevaluation as a critical component in sustained viral load change in HIV+ adults with alcohol problems. Ann Behav Med. 2010;40:176–83.PubMedCrossRef

62.

Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31:S149–53.PubMedCrossRef

63.

Mehta SH, Lucas G, Astemborski J, et al. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care. 2007;19:637–45.PubMedCrossRef

64.

Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27–39.PubMedCrossRef

65.

Rhodes T, Sarang A, Bobrik A, et al. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy. 2004;15:1–16.CrossRef

66.

Hernández SO, Martín LL, Isabel JAC, et al. Drug use and antiretroviral adherence in methadone maintenance patients: a longitudinal study. Int J Psychol Psychol Ther. 2009;9:365–81.

67.

Kresina TF, Bruce RD, McCance-Katz EF. Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Curr HIV Res. 2009;7:354–64.PubMedCrossRef

68.

Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152:704–11.PubMed

69.

Wang H, Zhou J, Huang L, et al. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J Clin Nurs. 2010;19:380–8.PubMedCrossRef

70.

Safren SA, O’Cleirigh C, Bullis JR. CBT for adherence and depression (CBT-AD) in HIV-infected injection drug users: an RCT. J Consult Clin Psychol. 2011;Under review.

71.

Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262–70.PubMedCrossRef

72.

Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185–94.PubMedCrossRef

73.

Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and antiretroviral treatment among HIV-infected Black women. J Commun Health. 2004;29:117–27.CrossRef

74.

Duncan R, Shapshak P, Page JB, et al. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV-infected African American women. Front Biosci. 2007;12:1488–95.PubMedCrossRef

75.

Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun. 2008;22:1257–62.PubMedCrossRef

76.

•• Baum M, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93–9. This study found that crack-cocaine users compared to non-users with HIV/AIDS were 2.14 times more likely to have a CD4 T-cell count decline to 200 cells/mL or below, and have a higher HIV viral load, independent of ART use.PubMedCrossRef

77.

Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2011;34:128–38.PubMedCrossRef

78.

Bell C, Metsch LR, Vogenthaler N, et al. Never in care: characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr. 2010;54:376–80.PubMed

79.

Traeger L, O’Cleirigh C, Perry N, Bedoya CA, Safren SA. Does Substance use interfere with acquisition and maintenance of HIV medication adherence skills? Poster presented at the International Association of Physicians in AIDS Care (IAPAC) 6th Annual International Conference on HIV Treatment and Prevention Adherence. Miami Beach, FL; May 22–24, 2011.

80.

Meade CS, Drabkin AS, Hansen NB, et al. Reductions in alcohol and cocaine use following a group coping intervention for HIV-positive adults with childhood sexual abuse histories. Addiction. 2010;105:1942–51.PubMedCrossRef

81.

Sikkema KJ, Hansen NB, Kochman A, et al. Outcomes from a group intervention for coping with HIV/AIDS and childhood sexual abuse: reductions in traumatic stress. AIDS Behav. 2007;11:49–60.PubMedCrossRef

82.

Woolridge EW, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29:358–67.PubMedCrossRef

83.

Prentiss D, Power R, Balmas G, et al. Patterns of Marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 2004;35:38–45.PubMedCrossRef

84.

de Jong BC, Prentiss D, McFarland W, et al. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38:43–6.PubMedCrossRef

85.

Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–80.PubMedCrossRef

86.

Corless IB, Lindgren T, Holzemer W, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18:172–93.PubMedCrossRef

87.

Deitz E, Clum GA, Chung S, et al. Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. J Adolesc Health. 2010;46:278–83.CrossRef

88.

Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2:194–9.PubMedCrossRef

89.

Marquez C, Mitchell SJ, Hare CB, et al. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004–2006. AIDS Care. 2009;21:575–82.PubMedCrossRef

90.

Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15:775–85.PubMedCrossRef

91.

McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse. 2009;35:34–7.PubMedCrossRef

92.

Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years—United States, 2009. Morbid Mortal Wkly Rep. 2010;59:1135–40.

93.

Fuster M, Estrada V, Fernandez-Pinilla MC, et al. Smoking cessation in HIV patients: rate of success and associated factors. HIV Med. 2009;10:614–9.PubMedCrossRef

94.

Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30:371–83.PubMedCrossRef

95.

Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100:1896–903.PubMedCrossRef

96.

Jaquet A, Ekouevi DK, Aboubakrine M, et al. Tobacco use and its determinants in HIV-infected patients on antiretroviral therapy in West African countries. Int J Tuberc Lung Dis. 2009;13:1433–9.PubMed

97.

•• Feldman DN, Feldman JG, Greenblatt R, et al. CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev. 2009;21:81–93. This study showed that tobacco smoking may limit the effectiveness of ART by promoting HIV-1 gene expression. PubMedCrossRef

98.

Humfleet GL, Delucchi K, Kelley K, et al. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21:54–64.PubMedCrossRef

99.

Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev. 2009;21:106–21.PubMedCrossRef

100.

Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev. 2009;21:14–27.PubMedCrossRef

101.

Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82:S71–9.PubMedCrossRef

102.

Webb MS, Vanable PA, Carey MP, Blair DC. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. AIDS Educ Prev. 2009;21:94–105.PubMedCrossRef

103.

Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV+ smokers: a randomized trial. Addiction. 2009;104:1891–900.PubMedCrossRef

104.

Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545–54.PubMedCrossRef

105.

Piper ME, Smith SS, Schlam TR, et al. Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J Consult Clin Psychol. 2010;78:13–23.PubMedCrossRef

106.

Zvolensky M, Kotov R, Bonn-Miller M, et al. Anxiety sensitivity as a moderator of association between smoking status and panic-related processes in a representative sample of adults. J Psychiatr Res. 2008;42:69–77.PubMedCrossRef

107.

•• Pisu M, Cloud G, Austin S, et al. Substance abuse treatment in an urban HIV clinic: who enrolls and what are the benefits? AIDS Care. 2010;22:348–54. This study showed that substance abuse treatment alone may not promote improvements in immunity or viral load suppression.PubMedCrossRef

108.

Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38:S402–8.PubMedCrossRef

109.

Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38:S409–13.PubMedCrossRef

110.

•• Berg KM, Litwin A, Li X, et al. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113:192–9. This randomized controlled trial showed that directly administered ART in conjunction with methadone maintenance therapy promotes ART adherence and HIV viral suppression.PubMedCrossRef

111.

Lucas GM, Mullen BA, McCaul ME, et al. Adherence, drug use, and treatment failure in a methadone clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21:564–74.PubMedCrossRef

112.

Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend. 2011;116:177–87.PubMedCrossRef

113.

Daughters SB, Magidson JF, Schuster RM, Safren SA. Act healthy: a combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users. Cogn Behav Pract. 2010;17:309–21.PubMedCrossRef

114.

O’Cleirigh C, Traeger L, Otto MW, et al. Medication adherence outcomes are mediated by treatment related changes in depression among a diverse HIV-infected sample in substance use treatment. Oral presentation at the International Association of Physicians in AIDS Care (IAPAC) 6th Annual International Conference on HIV Treatment and Prevention Adherence. Miami Beach, FL; May 22–24, 2011.

115.

Bush K, Kivlaham DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789–95.PubMedCrossRef

116.

Frank D, DeBenedetti AF, Volk RJ, et al. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups. J Gen Intern Med. 2008;23:781–7.PubMedCrossRef

117.

Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31:1208–17.PubMedCrossRef

118.

National Institute on Drug Abuse. Screening for drug use in general medical settings: A resource guide for providers. http://www.nida.nih.gov/nidamed/screening/. Accessed July 2011.

119.

World Health Organization. The ASSIST Project-Alcohol, Smoking and Substance Involvement Screen Test. http://www.who.int/substance_abuse/activities/assist/en/index.html. Accessed July 2011.

120.

Carrier E, Yee T, Holzwart RA. Coordination between emergency and primary care physicians. Natl Inst Health Care Reform Res Brief. 2011;3:1–11.

121.

Bradford JB. The promise of outreach for engaging and retaining out-of-care persons in HIV medical care. AIDS Patient Care STDS. 2007;21:S85–91.PubMed

122.

Bradford JB, Coleman S, Cunningham W. HIV systems navigation: An emerging model to improve HIV care access. AIDS Prevention Care STDS. 21:S49-58

Titel: Substance Use: Impact on Adherence and HIV Medical Treatment
verfasst von: Adam Gonzalez
Jennifer Barinas
Conall O’Cleirigh
Publikationsdatum: 01.12.2011
Verlag: Current Science Inc.
Erschienen in: Current HIV/AIDS Reports / Ausgabe 4/2011
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-011-0093-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Erratum to: Management of Fat Accumulation in Patients with HIV Infection

Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications

Secondary HIV Prevention: Novel Intervention Approaches to Impact Populations Most at Risk

A Global Perspective on Complementary and Alternative Medicine Use Among People Living with HIV/AIDS in the Era of Antiretroviral Treatment

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

Link to Slower Access to Care: What is the Stigma? An Indian Perspective